NCT01407276View on ClinicalTrials.gov

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 8, 2011

Primary Completion Date

March 23, 2012

Study Completion Date

March 23, 2012

Conditions
Chronic Renal InsufficiencyType 2 Diabetes Mellitus
Interventions
DRUG

Omarigliptin

Single oral dose of 3 mg (3 x 1-mg capsules)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01407276 - A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009) | Biotech Hunter | Biotech Hunter